Biofrontera is a pharmaceutical company specializing in prescription dermatology treatments, similar to a more focused Galderma.

• Ameluz®: A prescription drug in the form of a topical gel used in photodynamic therapy for the treatment of actinic keratosis and superficial basal cell carcinoma.
• BF-RhodoLED® lamp: A specialized medical device that emits red light, designed to activate Ameluz® during photodynamic therapy.

Biofrontera (symbol: BFRI) is a biopharmaceutical company that develops and commercializes dermatological products. Its primary products, such as the prescription drug Ameluz, are sold to healthcare providers (e.g., dermatologists' offices, hospitals, and clinics) indirectly through pharmaceutical wholesalers and distributors. Therefore, Biofrontera sells primarily to other companies and institutions (B2B).

While Biofrontera states in its public filings (20-F for the year ended December 31, 2022) that "no single customer accounted for 10% or more of our total revenue" (meaning specific individual customers are not required to be named by regulatory disclosure thresholds), the company does disclose its significant reliance on key distribution channels.

Biofrontera's major customers are pharmaceutical wholesalers that distribute its products to healthcare providers:

• In the United States: Biofrontera explicitly states that approximately 98% of its U.S. revenue from Ameluz is generated from "four major pharmaceutical wholesalers." While Biofrontera does not explicitly name these specific wholesalers in its public filings, the U.S. pharmaceutical distribution market is highly consolidated. Based on industry practice and market dominance, these major wholesalers are highly likely to include:
  • McKesson Corporation (Symbol: MCK)
  • AmerisourceBergen Corporation (Symbol: ABC)
  • Cardinal Health, Inc. (Symbol: CAH)
  (The identity of the fourth major wholesaler is not specified by Biofrontera but could be a smaller national or regional player).
• In Europe: Biofrontera sells its products directly to wholesalers and pharmacies. For Germany, the company indicates it mainly relies on "five pharmaceutical wholesalers." However, Biofrontera does not disclose the specific names of these European customer companies in its public filings.

• Biofrontera AG (Symbol: BFRA.DE)

Prof. Dr. Hermann Luebbert, Chief Executive Officer

Prof. Dr. Hermann Luebbert has served as the Chief Executive Officer for Biofrontera Inc. since May 2023. He founded the Biofrontera Group in 1997 and headed Biofrontera AG as CEO until December 2021. His background includes extensive academic research experience in the U.S. and Europe, along with ten years in research management at Sandoz Pharma and Novartis Pharma AG.

Eugene Fredrick Leffler, III, Chief Financial Officer

Eugene Fredrick Leffler, III, joined Biofrontera Inc. as Chief Financial Officer in 2022. He is an experienced financial executive with 15 years of leadership, financial management, consultancy, operations, and analytics experience across various private and public organizations, including growth-stage, private equity, and Fortune 100 companies. Prior to Biofrontera, he was a consultant at McKinsey & Co. and FTI Consulting, where he advised clients in corporate finance, strategy, public company readiness, and analytics across industries such as healthcare and private equity. He also held finance and accounting leadership positions at GE Energy and SunEdison.

George Jones, Chief Commercial Officer

George Jones serves as the Chief Commercial Officer for Biofrontera Inc., a role he took on effective August 25, 2025. He leads the company's commercial functions, including sales, marketing, and market access. Mr. Jones brings over 25 years of extensive commercial leadership experience in the specialty pharmaceutical and biotech sectors. His career includes instrumental roles at Currax Pharmaceuticals, Pernix Therapeutics, and Depomed, Inc., where he built and led commercial organizations, guided rapid growth, and successfully integrated product acquisitions.

Samantha Widdicombe, Senior Vice President of Sales & Marketing, Vice President Corporate Strategy and Key Accounts

Samantha Widdicombe joined Biofrontera Inc. in July 2023. She is responsible for Biofrontera Inc.'s corporate, KOL (Key Opinion Leader), and commercial strategies and strategic accounts. She has more than 25 years of sales and marketing leadership experience, with over a decade spent in the US Dermatology market.

Biofrontera's main product, Ameluz, addresses the actinic keratosis (AK) treatment market and the broader photodynamic therapy (PDT) market.

Ameluz (Actinic Keratosis Treatment)

• The U.S. actinic keratosis treatment market was valued at approximately USD 2.32 billion in 2022 and is projected to reach USD 2.94 billion by 2030, with a compound annual growth rate (CAGR) of 3.03% from 2023 to 2030.
• Another estimate for the U.S. actinic keratosis treatment market indicates a revenue of USD 2,543.6 million in 2024, expected to grow to USD 3,025.7 million by 2030, at a CAGR of 2.9% from 2025 to 2030.
• Globally, the actinic keratosis treatment market size was estimated at USD 6.4 billion in 2022 and is projected to reach USD 9.9 billion by 2032, growing at a CAGR of 4.6% from 2024 to 2033.

Photodynamic Therapy (PDT)

• The global photodynamic therapy market size was valued at USD 1.77 billion in 2023 and is projected to grow to USD 3.43 billion by 2032, exhibiting a CAGR of 7.7%.
• North America accounted for 36.72% of the global photodynamic therapy market share in 2023.

Xepi (Impetigo Treatment)

Biofrontera recently divested its U.S. license for Xepi (ozenoxacin cream, 1%) to Pelthos Therapeutics in November 2025. Therefore, Xepi is no longer a main product for Biofrontera. The addressable market size in USD for impetigo treatment for Biofrontera is null.

Biofrontera (BFRI) is expected to drive future revenue growth over the next 2-3 years through several key initiatives focused on expanding its photodynamic therapy (PDT) platform, primarily with its flagship product Ameluz, and enhancing its commercial strategies.

Here are 3-5 expected drivers of future revenue growth:

1. Expansion of Ameluz Indications and Market Penetration: Biofrontera is actively pursuing regulatory approvals for Ameluz in new dermatological conditions, which is expected to significantly broaden its addressable market. The company has completed enrollment in a Phase III trial for Ameluz in actinic keratosis (AK) on the trunk, neck, and extremities, with top-line clinical data readouts expected in the fourth quarter of 2025. Additionally, a Phase III plus one-year follow-up for superficial basal cell carcinoma (sBCC) has been finalized, with an FDA submission planned for the second half of 2025. Biofrontera also completed patient enrollment in a Phase 2b study of Ameluz for moderate-to-severe acne vulgaris, with top-line results anticipated in Q1 2026. Successful approvals for these expanded indications would open new significant revenue streams.
2. Increased Sales Volume of Ameluz and RhodoLED Lamps: The company is focused on enhancing its commercial execution to drive higher sales volume of Ameluz and increased placement of its RhodoLED lamp series. In the first half of fiscal year 2025, Ameluz unit sales volume increased by 9.5% year-over-year, surpassing 50,000 tubes sold. The installed base of RhodoLED lamps, including the newer RhodoLED XL lamps, reached an all-time high of over 700 units by Q2 2025, indicating successful sales strategies and market penetration. This growth is supported by new sales strategies such as revised hiring criteria and enhanced data analytics.
3. Improved Reimbursement and Extended Patent Protection for Ameluz: Effective July 1, 2025, the Centers for Medicare and Medicaid Services (CMS) began listing reimbursement for up to three tubes of Ameluz per treatment. This change is expected to enable broader usage of Ameluz and facilitate increased sales. Furthermore, Ameluz has received patent extension coverage through December 2043, providing long-term market exclusivity and a stable foundation for sustained revenue generation from its core product.

Share Issuance

• Biofrontera AG successfully completed a capital raise at the beginning of 2021.
• Biofrontera Inc. stockholders approved proposals for a reverse stock split and preferred share conversions in 2025 to maintain or regain compliance with Nasdaq listing requirements.
• The number of Biofrontera Inc. shares outstanding increased by 159.16% in one year.

Outbound Investments

• Biofrontera Inc. sold its U.S. license for Xepi (ozenoxacin) Cream to Pelthos Therapeutics Inc. for up to $10 million, including an initial $3 million payment and potential milestone payments, in November 2025.
• Biofrontera AG established a UK subsidiary in December 2022 to strengthen its sales activities in the country.
• Biofrontera AG entered into an agreement with Galenica AB for the promotion and distribution of Ovixan® in the United Kingdom in October 2024.

Capital Expenditures

• Biofrontera Inc.'s capital expenditures were -$5,000 in the last 12 months as of October 2025.
• Annual capital expenditures for Biofrontera Inc. were consistently low: -$0.01 million in 2024, -$0.01 million in 2023, -$0.04 million in 2022, and -$0.01 million in 2021.